Evotec SE Sponsored ADR
Evotec SE Sponsored ADR is a healthcare and life sciences depositary receipt representing Evotec SE, a drug discovery and development company headquartered in Hamburg, Germany. The company supports pharmaceutical and biotechnology partners with integrated research services across early-stage drug discovery, including target identification, screening, lead optimization, pharmacology, structural biology, and bioanalytics. Its work is organized around discovery and development platforms that help clients advance small molecules and biologics through preclinical research. Evotec SE also operates collaborative research programs and technology-enabled solutions that serve a broad range of therapeutic areas. As a Sponsored ADR, the asset provides U.S. investors with exposure to Evotec SE’s business in a U.S.-traded format while reflecting the company’s role in the global outsourced drug discovery market.
$1.38
-$0.04 (-2.82%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-7.08% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 1.1% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -€92M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€717M
▼ -1.1% YoY
Net Income (TTM)
-€197M
▲ +47.2% YoY
Op. Margin
-19.96%
▲ +2.8pp YoY
ROIC
-3.32%
▲ +0.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€174M
▲ +19.5% YoY
Op. Cash Flow (TTM)
-€115M
▲ +83.1% YoY
Net Debt
-€15M
Net Cash Position
Cash & Equiv.
€463M
3Y CAGR: +1.6%
Continue Research
Is Evotec SE Sponsored ADR (EVO) overvalued?
Evotec SE Sponsored ADR (EVO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Evotec SE Sponsored ADR scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Evotec SE Sponsored ADR a high-quality business?+
Evotec SE Sponsored ADR scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -20.0% operating margin and a -3.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Evotec SE Sponsored ADR a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh EVO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Drug Manufacturers - Specialty & Generic
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.